10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes

[1]  M. Dahl,et al.  Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. , 1997, Therapeutic drug monitoring.

[2]  M Ingelman-Sundberg,et al.  Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. , 1996, The Journal of pharmacology and experimental therapeutics.

[3]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[4]  L. Bertilsson,et al.  Polymorphic Drug Oxidation , 1996 .

[5]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[6]  J. Benítez,et al.  Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population , 1995, Clinical pharmacology and therapeutics.

[7]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[9]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[10]  M. Ingelman-Sundberg,et al.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.

[11]  M. Eichelbaum,et al.  Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. , 1991, DNA and cell biology.

[12]  L. Bertilsson,et al.  Enantioselective Hydroxylation of Nortriptyline in Human Liver Microsomes, Intestinal Homogenate, and Patients Treated with Nortriptyline , 1991, Therapeutic drug monitoring.

[13]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[14]  L. Bertilsson,et al.  Stereoselective disposition of racemic E‐10‐hydroxynortriptyline in human beings , 1989, Clinical pharmacology and therapeutics.

[15]  L. Bertilsson,et al.  Little anticholinergic effect of E‐10‐hydroxynortriptyline compared with nortriptyline in healthy subjects , 1987, Clinical pharmacology and therapeutics.

[16]  M. Scheinin,et al.  Disposition of single oral doses of E‐10‐hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects , 1986, Clinical pharmacology and therapeutics.

[17]  J. Lindsten,et al.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[18]  L. Bertilsson,et al.  Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. , 1985, British journal of clinical pharmacology.

[19]  L. Bertilsson,et al.  Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. , 1984, Life sciences.

[20]  L. Bertilsson,et al.  E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation , 1981, Clinical pharmacology and therapeutics.

[21]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[22]  L. Bertilsson,et al.  Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. , 1979, Life sciences.

[23]  G. Tucker,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE , 1977, The Lancet.

[24]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[25]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.

[26]  McLellan Gh.  Letter: SI units. , 1975 .

[27]  R. Kirk.  Experimental Design: Procedures for the Behavioral Sciences , 1970 .

[28]  J. Woo,et al.  Assessment of the relationship between plasma nortriptyline concentration and inhibition of salivation: Single-dose study , 1991 .

[29]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.

[30]  L. Bertilsson,et al.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. , 1985, Therapeutic drug monitoring.